Etelcalcetide regulatory update

Amgen submitted an NDA to FDA and an MAA to EMA for etelcalcetide to treat secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis. The IV peptide calcimimet...